Evidence map›Paper›PMID 30401680›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2019

Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.

David R Maguire, Lisa R Gerak, James H Woods, Stephen M Husbands, Alex Disney, Charles P France

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.The Journal of pharmacology and experimental therapeutics · 2021
    Article
  19. Countermeasures for Preventing and Treating Opioid Overdose.Clinical pharmacology and therapeutics · 2021
    Review
  20. Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

David R MaguireDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).
Lisa R GerakDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).
James H WoodsDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).
Stephen M HusbandsDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).
Alex DisneyDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.).
Charles P FranceDepartment of Pharmacology (D.R.M., L.R.G., J.H.W., C.P.F.), Department of Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (D.R.M., L.R.G., J.H.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (S.M.H., A.D.) france@uthscsa.edu.
The University of Texas at San Antonio · USThe University of Texas Health Science Center at San Antonio · USUniversity of Bath · GB

Funding

DISCRIMINATIVE STIMULUS OF OPIOID WITHDRAWALR01DA005018 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FRANCE, CHARLES P · 1988 to 2025
$8.8M
Narcotic Drug and Opioid Peptide Basic Research projectP01DA000254 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOODS, JAMES H · 2003 to 2006
$5.0M
DISCOVERY OF NEW TREATMENTS FOR INTRAVENOUS DRUG ABUSER01DA007315 · NIDA · UNIVERSITY OF BRISTOL · PI HUSBANDS, STEPHEN M, TRAYNOR, JOHN R. · 1991 to 2019
$4.8M
A novel opioid receptor antagonist for treating abuse and overdoseR01DA048417 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FRANCE, CHARLES P · 2019 to 2023
$2.6M
NIDA NIH HHS P01 DA000254NIDA NIH HHS R01 DA005018NIDA NIH HHS R01 DA007315NIDA NIH HHS R01 DA048417
6 · The paper itself

Abstract

Opioid abuse remains a serious public health challenge, despite the availability of medications that are effective in some patients (naltrexone, buprenorphine, and methadone). This study explored the potential of a pseudoirreversible mu-opioid receptor antagonist [methocinnamox (MCAM)] as a treatment for opioid abuse by examining its capacity to attenuate the reinforcing effects of mu-opioid receptor agonists in rhesus monkeys. In one experiment, monkeys responded for heroin (

Indexed as

Analgesics, OpioidAnimalsCinnamatesDrug-Seeking BehaviorFemaleMacaca mulattaMaleMorphine DerivativesNaltrexoneNarcotic AntagonistsReceptors, Opioid, muSelf AdministrationTime FactorsAnalgesics, OpioidCinnamatesmethocinnamoxMorphine DerivativesNaltrexoneNarcotic AntagonistsReceptors, Opioid, mu

Identifiers

PMID30401680
PMCPMC11046729
OpenAlexW2899951388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.